CG Oncology Rockets On Its Johnson & Johnson-Rivaling Cancer Drug
In This Article:
Shares of CG Oncology catapulted Monday after the biotech unveiled promising results for a J&J-rivaling bladder cancer treatment.
Oops, something went wrong
Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Shares of CG Oncology catapulted Monday after the biotech unveiled promising results for a J&J-rivaling bladder cancer treatment.